言語を選択
新規登録

NSP8

NSP8 詳細

英語名SARS-CoV-2-3C-like-proteinase市販薬剤の数7
治験薬の数27ターゲットの別称Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO
研究＆開発段階Approved
英語名SARS-CoV-2-3C-like-proteinase
ターゲットの別称Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO
市販薬剤の数7
治験薬の数27
研究＆開発段階Approved

NSP8 製品リスト

  • 属性

    Protein (1)

  • 製品ライブラリ

    オンライン (1)

  • 種

    SARS-CoV-2 (1)

  • タグ

    His Tag (1)

  • マーカー

    Unconjugated (1)

製品番号種発現システム製品説明タンパク質の構造純度特性
NS8-C5149
SARS-CoV-2
E. coli
SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag
総数量1
  • 1

NSP8バックグランド

NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.

NSP8分子の別称

NSP8,nsp8,Non-structural protein 8

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
EbselenSPI-1005; SPI-3005; PZ-51; DR-3305Phase 3 ClinicalDaiichi Sankyo Co Ltd, Sound Pharmaceuticals IncBipolar Disorder; Cochlear Diseases; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Hearing Loss; Hearing Loss, Noise-Induced; Lung Neoplasms; Meniere Disease; Neoplasms; Nervous System Diseases; Ototoxicity; Tinnitus
詳細
SecutrelvirS-892216Phase 3 ClinicalShionogi & Co LtdCoronavirus Disease 2019 (COVID-19); Renal Insufficiency
詳細
ibuzatrelvirPF-07817883; PF-7817883Phase 3 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19)
詳細
MprosevirWPV-01Phase 3 ClinicalWestlake UniversityCoronavirus Disease 2019 (COVID-19)
詳細
QLS-1128QLS-1128Phase 3 ClinicalQilu Pharmaceutical Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
MIR-19MIR-19Phase 3 ClinicalSt. Petersburg Scientific Research Institute of Vaccines and SeraCoronavirus Disease 2019 (COVID-19)
詳細
BofutrelvirFB-2001; DC-402234Phase 3 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
詳細
NirmatrelvirPF-07321332Phase 3 ClinicalPfizer AsCoronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome
詳細
CDI-988CDI988Phase 2 ClinicalCocrystal Pharma IncCoronavirus Disease 2019 (COVID-19); Norovirus Infections
詳細
Travatrelvir83-0060; TRX-01Phase 2 ClinicalTraws Pharma IncCoronavirus Disease 2019 (COVID-19)
詳細
DeusitrelvirSHEN-211; SHEN211Phase 2 ClinicalHubei JKT BioPharma Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
HS-10517HS-10517; HS10517Phase 2 ClinicalJiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
ZevotrelvirEDP-235Phase 2 ClinicalEnanta Pharmaceuticals IncCoronavirus Disease 2019 (COVID-19)
詳細
TollovirPhase 2 ClinicalTodos Medical LtdCoronavirus Disease 2019 (COVID-19)
詳細
SNB-011SNB-01; SNB-011Phase 2 ClinicalSyneurx International (Taiwan) CorpCoronavirus Disease 2019 (COVID-19)
詳細
PomotrelvirPBI-0451Phase 1 ClinicalPardes Biosciences IncCoronavirus Disease 2019 (COVID-19)
詳細
CMX-990CMX-990; CMX990Phase 1 ClinicalThe Scripps Research Institute IncCoronavirus Disease 2019 (COVID-19)
詳細
WPV-02WPV-02; WPV02Phase 1 ClinicalWestlake Pharmaceuticals (Hangzhou) Co LtdVirus Diseases
詳細
ISM-3312ISM-3312Phase 1 ClinicalInsilico Medicine LtdCoronavirus Disease 2019 (COVID-19)
詳細
LimnetrelvirABBV-903Phase 1 ClinicalAbbvie Inc
詳細
SAL-0133SAL-0133Phase 1 ClinicalShenzhen Salubris Pharmaceuticals Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
SYH-2055SYH-2055Phase 1 ClinicalCSPC Pharmaceutical Group LtdCoronavirus Disease 2019 (COVID-19)
詳細
AtilotrelvirGST-HG171Phase 1 ClinicalFujian Guangsheng Zhonglin Biotechnology Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
ALG-097558ALG-097558Phase 1 ClinicalAligos Therapeutics Inc, Centre for Drug Design and Discovery, Rega Institute for Medical ResearchCoronavirus Disease 2019 (COVID-19)
詳細
ASC11ASC-11Phase 1 ClinicalAscletis Pharma IncCoronavirus Disease 2019 (COVID-19)
詳細
LufotrelvirPF-07304814Phase 1 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19); Virus Diseases
詳細
GS221GS-221; GS221ClinicalGrand Pharmaceutical （China） Co LtdCoronavirus Disease 2019 (COVID-19)
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
OlgotrelvirSTI-1558; STI1558ApprovedTexas A&M UniversityOvydso, 奥维宁Mainland ChinaCoronavirus Disease 2019 (COVID-19)Zhejiang Acea Pharmaceutical Co Ltd2025-10-28Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive
詳細
Atilotrelvir/RitonavirApprovedFujian Guangsheng Zhonglin Biotechnology Co Ltd泰中定Mainland ChinaCoronavirus Disease 2019 (COVID-19)Fujian Guangsheng Zhonglin Biotechnology Co Ltd2023-11-23Coronavirus Disease 2019 (COVID-19)
詳細
SimnotrelvirSIM-0417; SSD-8432; VV-934ApprovedJiangsu Simcere Pharmaceutical Co LtdMainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Coronavirus Disease 2019 (COVID-19)
詳細
LeritrelvirRAY003; RAY-003; RAY-1216ApprovedGuangdong Raynovent Biotech Co Ltd乐睿灵Mainland ChinaCoronavirus Disease 2019 (COVID-19)Guangdong Raynovent Biotech Co Ltd2023-03-23Acute Kidney Injury; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency
詳細
Simnotrelvir/RitonavirSIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / RitonavirApprovedJiangsu Simcere Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Wuhan Institute Of Virology, Chinese Academy Of Sciences先诺欣Mainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Renal Insufficiency
詳細
Ensitrelvir Fumaric AcidS-217622ApprovedHokkaido University, Shionogi & Co LtdXocovaJapanCoronavirus Disease 2019 (COVID-19)Shionogi & Co Ltd2022-11-22Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome; Renal Insufficiency
詳細
Nirmatrelvir/RitonavirApprovedPfizer IncPaxlovid, 瑞派乐EUCoronavirus Disease 2019 (COVID-19)Pfizer Europe Ma Eeig2022-01-28Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Post-Acute COVID-19 Syndrome; Postural Orthostatic Tachycardia Syndrome
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
共有：

採用情報法的規制サイトマッププライバシーポリシー利用規約
ウェブサイトに関するフィードバック
お問い合わせ

お問い合わせ
グローバル：+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8